NUPLAZID has a proven safety profile with no impact on motor function1
Once‑daily NUPLAZID 34 mg demonstrated similar effects to placebo on activities of daily living and motor control1
- Unified Parkinson’s Disease Rating Scale Parts II and III (UPDRS II+III) is a clinical rating scale that assesses motor function and the impact of motor function on activities of daily living
CI=confidence interval; UPDRS=Unified Parkinson’s Disease Rating Scale.
* Difference (drug minus placebo) in least-squares mean.
† Non-inferiority criteria required that the upper bound of the 95% CI not exceed 5.
Adverse reactions in placebo-controlled studies of 6-week treatment duration and reported in ≥2% of patients receiving once‑daily NUPLAZID and greater than placebo1
*Based upon 6-week placebo-controlled studies.1
†Hallucination includes visual, auditory, tactile, and somatic hallucinations.1
Meet Susan, a 78-year-old woman, diagnosed with Parkinson’s disease 9 years ago. Susan often sees children playing inside the living room and actively talks to them although no one is there . She also sees insects crawling on the walls throughout her house.
- Reduction of carbidopa/levodopa made, but led to worsening of motor function
- Susan’s daughter is worried as her mother is bringing food into the living room that is left uneaten and attracting bugs, and is concerned this is happening too often
- When asked about this, Susan responds that the children may be hungry and need food
When you see a patient like Susan, start treatment with NUPLAZID.View additional profiles